Astellas acquires Iveric for US$5.9bn

Astellas Pharma has acquired Iveric Bio for US$5.9bn, to further its goal of becoming a world-class ophthalmology entity with a focus on blindness and regeneration, said Astellas in a statement.  


The acquisition will absorb US company Iveric’s pipeline, which includes avacincaptad pegol to treat geographic atrophy (GA) (currently under US Food and Drug Administration review) and autosomal recessive Stargardt disease; IC-500, an HtrA1 inhibitor for GA treatment; and gene therapy products mini-CEP290 for Leber congenital amaurosis type 10, mini-ABCA4 for autosomal recessive Stargardt disease and mini-USH2A to treat Usher syndrome type 2A.  


Headquartered in Japan, Astellas’ lead ophthalmic product is ASP7317 (human embryonic stem-cell-derived retinal pigment epithelial cells), for the treatment of GA secondary to age-related macular degeneration and Stargardt disease and is in phase 1b clinical trial. Prograf (tacrolimus), an immunosuppressant used in corneal and other organ transplants, is among the company’s existing products. 


Bottom Banner Advert